2. Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis
  3. Endogenous Metabolite COX Interleukin Related Glutathione Peroxidase TNF Receptor
  4. Taurohyodeoxycholic acid

Taurohyodeoxycholic acid  (Synonyms: 牛磺猪去氧胆酸)

目录号: HY-114360 纯度: 99.73%
COA 产品使用指南 技术支持

Taurohyodeoxycholic acid 是一种口服有效的 6α-羟基化胆汁酸。Taurohyodeoxycholic acid 可降低结肠髓过氧化物酶 (MPO) 活性、TNF-α、IL-6 血清水平以及 COX-2 的表达。Taurohyodeoxycholic acid 通过调节 Th1/Th2 和 Th17/Treg 细胞平衡缓解三硝基苯磺酸诱导的溃疡性结肠炎。Taurohyodeoxycholic acid 可改善高脂饮食诱导的小鼠非酒精性脂肪肝病。Taurohyodeoxycholic acid 能预防 Taurochenodeoxycholic acid (HY-N2027) 诱导的胆瘘大鼠肝毒性。Taurohyodeoxycholic acid 可用于非酒精性脂肪肝病 (NAFLD)、结肠炎和胆瘘的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Taurohyodeoxycholic acid

Taurohyodeoxycholic acid Chemical Structure

CAS No. : 2958-04-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1319
In-stock
5 mg ￥1080
In-stock
10 mg ￥1560
In-stock
25 mg ￥2875
In-stock
50 mg ￥4312
In-stock
100 mg 现货 询价
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Taurohyodeoxycholic acid:

Taurohyodeoxycholic acid 相关抗体

Top Publications Citing Use of Products

查看 COX 亚型特异性产品:

查看所有亚型
COX COX-1 COX-2 COX-3

查看 Interleukin Related 亚型特异性产品:

查看所有亚型
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

查看 TNF Receptor 亚型特异性产品:

查看所有亚型
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula[1][2][3][4].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
CHO EC50
24.2 μM
Compound: 10a, tauro
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
[PMID: 18307294]
体外研究
(In Vitro)

Taurohyodeoxycholic acid (25-100 μM, 12 h) 在棕榈酸 (Palmitic acid (HY-N08307))/油酸 (Oleic acid (HY-N1446)) 处理的 AML-12 细胞中呈剂量依赖性降低甘油三酯水平[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Taurohyodeoxycholic acid 相关抗体:
体内研究
(In Vivo)

Taurohyodeoxycholic acid (200 mg/kg，每日口服给药，持续 17 天) 通过减少脂质蓄积改善高脂饮食诱导的小鼠非酒精性脂肪肝病[1]。
Taurohyodeoxycholic acid (20-100 mg/kg，每日口服给药或灌胃给药，持续 7 天) 可以缓解三硝基苯磺酸 (TNBS) 诱导的小鼠结肠炎[2][4]。
Taurohyodeoxycholic acid (4 mg/kg/min (8 μmol/min/kg)，静脉注射 1 小时) 可预防牛磺鹅去氧胆酸(Taurochenodeoxycholic acid) (HY-N2027) 诱导的胆瘘大鼠肝毒性[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: High-fat diet was fed to 4-week-old male C57BL/6 mice to induce nonalcoholic fatty liver disease[1].
Dosage: 200 mg/kg
Administration: p.o. daily for 17 days
Result: Reduced body weight, liver index, and epididymal white adipose tissue index in high-fat diet-fed mice.
Decreased serum triglyceride, total cholesterol, and hepatic triglyceride levels.
Improved hepatic steatosis and glucose homeostasis (enhanced glucose tolerance and insulin sensitivity).
Upregulated hepatic CYP7B1 protein expression and downregulated hepatic CYP7A1 and CD36 protein expressions.
Dose-dependently decreased triglyceride levels in palmitic acid/oleic acid-treated AML-12 cells.
Animal Model: Trinitrobenzene sulfonic acid (100 μL of 2.0 mg TNBS in 50% EtOH) was intrarectally administered to 7-8-week-old male SPF Kunming mice to induce ulcerative colitis[2].
Dosage: 20, 40, 80 mg/kg
Administration: p.o. daily for 7 days
Result: Alleviated TNBS-induced colitis by improving body weight, colon length, spleen weight, histological characteristics, and reducing MPO activity in mice.
Reduced Th1-/Th17-related cytokines (IFN-γ, IL-12, p70, IL-6, IL-17A, IL-21, IL-22, TNF-α) and transcription factors (T-bet, STAT4, RORγt, STAT3) in the colon.
Increased Th2-/Treg-related cytokines (IL-4, IL-10, TGF-β1) and transcription factors (GATA3, STAT6, Foxp3, Smad3) in the colon.
Inhibited IFN-γ, IL-17A, T-bet, RORγt expressions and improved IL-4, IL-10, GATA3, Foxp3 expressions in the spleen.
Restored the proportion of Th1, Th2, Th17, Treg cells and balanced Th1/Th2 and Th17/Treg immune response in colitis mice.
Animal Model: Taurochenodeoxycholic acid was intravenously infused into bile fistula Sprague-Dawley rats (200-250 g)[3].
Dosage: 4 mg/kg/min (8 μmol/min/kg)
Administration: i.v. for 1 h
Result: Increased bile flow, with maximum flow rate twice that of the control group after 60 minutes.
Enhanced biliary secretion of total bile acids, reaching a maximum rate of 17.5 μmol/min/kg at 60 minutes; Increased phospholipid secretion, with a peak of 0.65 μmol/min/kg.
Restored biliary calcium secretion; reduced biliary leakage of alkaline phosphatase to levels similar to the control group and decreased lactate dehydrogenase leakage.
Increased the maximum biliary secretion rate of taurochenodeoxycholic acid to 7.6 μmol/min/kg, with its own maximum secretion rate reaching 7.9 μmol/min/kg.
Animal Model: Trinitrobenzene sulfonic acid (TNBS, 0.5 mg in 0.1 ml of 50% ethanol) was intrarectally administered into the colon of 22-25 g male Balb/c mice via a 3.5F catheter inserted 4 cm proximal to the anus to induce ulcerative colitis model[4].
Dosage: 25, 50, 100 mg/kg
Administration: i.g., daily for 7 days
Result: Alleviated TNBS-induced colitis by improving body weight, reducing macroscopic colonic damage and histopathological changes, and decreasing colonic MPO activity in mice.
Reduced serum levels of pro-inflammatory cytokines (TNF-α, IL-6) and decreased the expression of COX-2 in the colon.
分子量

499.70

Formula

C26H45NO6S
CAS 号
性状

固体

颜色

White to off-white

中文名称

牛磺猪去氧胆酸
结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
细胞实验： 

DMSO 中的溶解度 : 100 mg/mL (200.12 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0012 mL 10.0060 mL 20.0120 mL
5 mM 0.4002 mL 2.0012 mL 4.0024 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验：

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.00 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.00 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

    2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.73%

COA (286 KB) HNMR (337 KB) RP-HPLC (203 KB) MS (70 KB)

产品使用指南 (1538 KB)
参考文献

Taurohyodeoxycholic acid 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0012 mL 10.0060 mL 20.0120 mL 50.0300 mL
5 mM 0.4002 mL 2.0012 mL 4.0024 mL 10.0060 mL
10 mM 0.2001 mL 1.0006 mL 2.0012 mL 5.0030 mL
15 mM 0.1334 mL 0.6671 mL 1.3341 mL 3.3353 mL
20 mM 0.1001 mL 0.5003 mL 1.0006 mL 2.5015 mL
25 mM 0.0800 mL 0.4002 mL 0.8005 mL 2.0012 mL
30 mM 0.0667 mL 0.3335 mL 0.6671 mL 1.6677 mL
40 mM 0.0500 mL 0.2502 mL 0.5003 mL 1.2508 mL
50 mM 0.0400 mL 0.2001 mL 0.4002 mL 1.0006 mL
60 mM 0.0334 mL 0.1668 mL 0.3335 mL 0.8338 mL
80 mM 0.0250 mL 0.1251 mL 0.2502 mL 0.6254 mL
100 mM 0.0200 mL 0.1001 mL 0.2001 mL 0.5003 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Taurohyodeoxycholic acid2958-04-5牛磺猪去氧胆酸Endogenous MetaboliteCOXInterleukin RelatedGlutathione PeroxidaseTNF ReceptorCyclooxygenaseILTumor Necrosis Factor ReceptorTNFRTh1/Th2Th17/TregCytokinenonalcoholic fatty liver disease (NAFLD)colitisbiliary fistulaInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Taurohyodeoxycholic acid
目录号：
HY-114360
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z